VCEL
Vericel Corporation
stockNASDAQ
about vericel founded in 1989, vericel (formerly aastrom biosciences), is dedicated to the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. the company markets two cell therapy products in the united states, carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee and epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. vericel is also developing maci, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-t, a patient specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (dcm). to fulfill vericel's mission of helping people with severe diseases and conditions rea
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 40.25 | 2026-10-14 | +1.76% | 2.122 |
| 1M | 39.55 | 2026-09-21 | +3.56% | 1.166 |
| 3M | 46.14 | 2026-07-21 | -11.23% | 0.407 |
| 6M | 33.67 | 2026-04-21 | +21.65% | 0.166 |
| 1Y | 36.45 | 2025-10-21 | +12.37% | 0.756 |
| 2Y | 41.18 | 2024-10-21 | -0.53% | — |
| 5Y | 50.57 | 2021-10-21 | -19.00% | 1.397 |
Vericel Corporation (NASDAQ:VCEL) stock price today is $40.96, and today's volume is 359,157. VCEL is up 0.936% today. The 30 day average volume is 539,083. VCEL market cap is $2.10B with 51.21M shares outstanding.